212,049 Shares in Stoke Therapeutics, Inc. $STOK Purchased by Checkpoint Capital L.P.

Checkpoint Capital L.P. purchased a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 212,049 shares of the company’s stock, valued at approximately $4,983,000. Stoke Therapeutics comprises approximately 1.7% of Checkpoint Capital L.P.’s holdings, making the stock its 8th largest position.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Generali Investments Management Co LLC acquired a new position in shares of Stoke Therapeutics during the 3rd quarter valued at about $41,000. BNP Paribas Financial Markets boosted its position in shares of Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period. Osaic Holdings Inc. grew its holdings in Stoke Therapeutics by 263.3% in the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock valued at $85,000 after purchasing an additional 5,427 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey increased its position in Stoke Therapeutics by 33.2% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock worth $108,000 after purchasing an additional 2,384 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on STOK shares. Chardan Capital increased their price target on shares of Stoke Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Canaccord Genuity Group boosted their price objective on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, January 5th. UBS Group set a $50.00 price objective on Stoke Therapeutics in a report on Monday, December 15th. HC Wainwright increased their target price on Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.25.

Insider Buying and Selling at Stoke Therapeutics

In related news, insider Arthur Tzianabos sold 4,355 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total transaction of $174,200.00. Following the sale, the insider directly owned 31,339 shares in the company, valued at approximately $1,253,560. This trade represents a 12.20% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Adrian R. Krainer sold 33,243 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total value of $1,321,076.82. Following the transaction, the director directly owned 283,302 shares in the company, valued at $11,258,421.48. This trade represents a 10.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 9.50% of the stock is currently owned by corporate insiders.

Stoke Therapeutics Stock Performance

NASDAQ STOK opened at $33.19 on Friday. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of 49.54 and a beta of 1.07. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $40.22. The company’s 50 day moving average price is $32.71 and its 200 day moving average price is $29.63.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.